NephroGenex (NRX) Initiates Pivotal Phase 3 Study With Novel Treatment To Slow Progression Of Diabetic Kidney Disease
6/19/2014 11:30:01 AM
RESEARCH TRIANGLE PARK, N.C.,--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced it has initiated patient enrollment in the first of two pivotal Phase 3 studies in the PIONEER program for oral Pyridorin. The trial will evaluate the safety and efficacy of Pyridorin in slowing disease progression in patients with diabetic nephropathy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by